Abstract
MicroRNAs (miRNAs) are confirmed to be tumor promoters or suppressors in multiple squamous cell carcinomas (SCCs). miR‐99a‐5p has been demonstrated to be downregulated in cancerous tissues, but its functional role in head and neck SCC (HNSCC) and its mechanism of action have not been fully elucidated. Here, we studied the expression of miR‐99a‐5p in HNSCC and performed a clinical value assessment and then extracted mature expression data from The Cancer Genome Atlas (TCGA) and microarrays from Gene Expression Omnibus (GEO). Furthermore, biological analysis was constructed via online prediction tools. The results revealed that miR‐99a‐5p expression was markedly lower in HNSCC tissues than in normal tissues, which also showed significance in the prognosis of HNSCC. However, its diagnostic value could not be verified due to the lack of body fluid samples. Additionally, miR‐99a‐5p was expressed at higher levels in patients with low histological grade neoplasms than those with high histological grade neoplasms. The age of the patient might also be a possible clinical parameter affecting miR‐99a‐5p expression. Furthermore, miR‐99a‐5p significantly influenced HNSCC progression by regulating the PI3K‐Akt signaling pathway, in which the key target genes were upregulated in 519 HNSCC tissues compared to 44 normal tissues, as determined by the Gene Expression Profiling Interactive Analysis (GEPIA). In conclusion, our study may provide insights into the expression and mechanism of miR‐99a‐5p in HNSCC. Further studies are required to elucidate the role of miR‐99a‐5p and its potential clinical applications for HNSCC.
Highlights
MicroRNAs are confirmed to be tumor promoters or suppressors in multiple squamous cell carcinomas (SCCs). miR-99a-5p has been demonstrated to be downregulated in cancerous tissues, but its functional role in head and neck SCC (HNSCC) and its mechanism of action have not been fully elucidated
Statistical analysis based on the IIIuminaHiseq platform (Table 1) revealed that miR-99a-5p was expressed at a lower level in HNSCC tissues than in normal tissues (7.987 Æ 1.467 vs 10.348 Æ 0.625, respectively; P < 0.001)
When statistical analysis was carried out using a combination of the IIIuminaHiseq and IIIuminaGA platforms (Table 2), the results revealed that miR-99a-5p was expressed at lower levels in HNSCC tissues than in adjacent normal tissues (8.028 Æ 1.498 vs 10.348 Æ 0.625, respectively, P < 0.001)
Summary
MicroRNAs (miRNAs) are confirmed to be tumor promoters or suppressors in multiple squamous cell carcinomas (SCCs). miR-99a-5p has been demonstrated to be downregulated in cancerous tissues, but its functional role in head and neck SCC (HNSCC) and its mechanism of action have not been fully elucidated. MiR-99a-5p has been demonstrated to be downregulated in cancerous tissues, but its functional role in head and neck SCC (HNSCC) and its mechanism of action have not been fully elucidated. Head and neck SCC (HNSCC) has attracted the Abbreviations BP, biological process; CC, cellular component; DAVID, Database for Annotation, Visualization, and Integrated Discovery; FN, false negative; FP, false positive; GEO, Gene Expression Omnibus; GEPIA, Gene Expression Profiling Interactive Analysis; GO, gene ontology; HNSCC, head and neck squamous cell carcinoma; IGF1R, insulin-like growth factor 1 receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes; LR, likelihood ratio; MF, molecular function; MTOR, mechanistic target of rapamycin; PDGFRB, platelet-derived growth factor receptor, beta polypeptide; PIK3CD, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit data; PPI, protein–protein interaction; ROC, receiver operating characteristic; SCC, squamous cell carcinoma; TCGA, The Cancer Genome Atlas; TN, true negative; TNM, tumor, node, and metastasis; TP, true positive. The increasing morbidity, mortality, and complex pathological changes of HNSCC urgently necessitate more effective means for its diagnosis and treatment, especially targeted treatments based on the further exploration of novel biomarkers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.